User Fee Renewal Negotiations Beginning This Week

Talks between US FDA and industry to extend the generic drug and prescription drug user fee programs may last into 2021.

Businessman working with calculator and document data - Image
User fee reauthorization negotiations will be virtual rather than in-person. • Source: Shutterstock

Formal negotiations between industry and the US Food and Drug Administration to reauthorize the generic drug and prescription drug user fees will begin this month, with talks for one program opening this week.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from User Fees

More from Pathways & Standards

Pink Sheet Podcast: More US FDA Departures, Makary On Combined AE Database, ‘Conditional’ Approval

 

Pink Sheet reporter and editors discuss the most recent senior staff departures at the FDA and their impact on the agency, as well as Commissioner Martin Makary’s plans for a new approval pathway and a combined adverse event database as outlined in an interview with a podcast host.

Brazil’s ANVISA Clarifies Registration Procedures For Biologicals

 

Brazil’s drug regulator has published a new technical note updating guidelines on registration and post-registration procedures for biological products.

Postmarketing Surprise Is Latest Plot Twist For Novavax’s COVID-19 Vaccine BLA

 

Three weeks after its user fee goal date, the FDA demanded a postmarketing commitment “to generate additional data,” Novavax said.